These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 31550408)

  • 21. Oral fosfomycin versus ciprofloxacin in women with E.coli febrile urinary tract infection, a double-blind placebo-controlled randomized controlled non-inferiority trial (FORECAST).
    Ten Doesschate T; van Mens SP; van Nieuwkoop C; Geerlings SE; Hoepelman AIM; Bonten MJM
    BMC Infect Dis; 2018 Dec; 18(1):626. PubMed ID: 30518334
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Fosfomycin: past, present and future].
    Baylan O
    Mikrobiyol Bul; 2010 Apr; 44(2):311-21. PubMed ID: 20549968
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevention of recurrent lower urinary tract infections by long-term administration of fosfomycin trometamol. Double blind, randomized, parallel group, placebo controlled study.
    Rudenko N; Dorofeyev A
    Arzneimittelforschung; 2005; 55(7):420-7. PubMed ID: 16080282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The revival of fosfomycin.
    Michalopoulos AS; Livaditis IG; Gougoutas V
    Int J Infect Dis; 2011 Nov; 15(11):e732-9. PubMed ID: 21945848
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of reflex fosfomycin susceptibility testing on the utilization of carbapenems for definitive extended-spectrum β-lactamase Escherichia coli urinary tract infection treatment.
    Deemer K; Grey J; Fronczek C; Marr K
    Am J Health Syst Pharm; 2020 Nov; 77(Supplement_4):S105-S110. PubMed ID: 32840305
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical effects of 2 days of treatment by fosfomycin calcium for acute uncomplicated cystitis in women.
    Matsumoto T; Muratani T; Nakahama C; Tomono K
    J Infect Chemother; 2011 Feb; 17(1):80-6. PubMed ID: 20694571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The use of oral fosfomycin-trometamol in patients with catheter-associated urinary tract infections (CAUTI): new indications for an old antibiotic?
    Cai T; Cocci A; Verze P; Rizzo M; Palmieri A; Liguori G; Trombetta C; Adembri C; Carini M; Bartoletti R; Wagenlehner FM; Bonkat G; Mirone V; Bjerklund Johansen TE; Novelli A
    J Chemother; 2018 Sep; 30(5):290-295. PubMed ID: 30843774
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
    Rodríguez-Baño J; Alcalá JC; Cisneros JM; Grill F; Oliver A; Horcajada JP; Tórtola T; Mirelis B; Navarro G; Cuenca M; Esteve M; Peña C; Llanos AC; Cantón R; Pascual A
    Arch Intern Med; 2008 Sep; 168(17):1897-902. PubMed ID: 18809817
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fosfomycin for the treatment of resistant gram-negative bacterial infections. Insights from the Society of Infectious Diseases Pharmacists.
    Reffert JL; Smith WJ
    Pharmacotherapy; 2014 Aug; 34(8):845-57. PubMed ID: 24782335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Perioperative fosfomycin disodium prophylaxis against urinary tract infection in renal transplant recipients: a randomized clinical trial.
    Rosado-Canto R; Parra-Avila I; Tejeda-Maldonado J; Kauffman-Ortega C; Rodriguez-Covarrubias FT; Trujeque-Matos M; Cruz-Martínez R; Maravilla-Franco E; Criollo-Mora E; Arreola-Guerra JM; Morales-Buenrostro LE; Sifuentes-Osornio J
    Nephrol Dial Transplant; 2020 Nov; 35(11):1996-2003. PubMed ID: 31883327
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potential role of fosfomycin in the treatment of community-acquired lower urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.
    Wilson DT; May DB
    Am J Ther; 2013; 20(6):685-90. PubMed ID: 21768870
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of MDR urinary tract infections with oral fosfomycin: a retrospective analysis.
    Seroy JT; Grim SA; Reid GE; Wellington T; Clark NM
    J Antimicrob Chemother; 2016 Sep; 71(9):2563-8. PubMed ID: 27246234
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of Fosfomycin for Complicated or Multidrug-Resistant Urinary Tract Infections: Patient Characteristics and Outcomes.
    Giancola SE; Mahoney MV; Hogan MD; Raux BR; McCoy C; Hirsch EB
    Chemotherapy; 2017; 62(2):100-104. PubMed ID: 27788499
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Experience of using the antibacterial drug Fosfomycin Esparma for the treatment of acute uncomplicated cystitis in women].
    Aboyan IA; Orlov YN; Voloshina OA; Orlov NV; Pavlov DS
    Urologiia; 2019 Sep; (4):20-25. PubMed ID: 31535800
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful Treatment of Urinary Tract Infection in Kidney Transplant Recipients Caused by Multiresistant Klebsiella pneumoniae Producing New Delhi Metallo-Beta-Lactamase (NDM-1) With Strains Genotyping.
    Wilkowski P; Ciszek M; Dobrzaniecka K; Sańko-Resmer J; Łabuś A; Grygiel K; Grochowiecki T; Młynarczyk G; Pączek L
    Transplant Proc; 2016 Jun; 48(5):1576-9. PubMed ID: 27496450
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections: A Randomized Clinical Trial.
    Sojo-Dorado J; López-Hernández I; Rosso-Fernandez C; Morales IM; Palacios-Baena ZR; Hernández-Torres A; Merino de Lucas E; Escolà-Vergé L; Bereciartua E; García-Vázquez E; Pintado V; Boix-Palop L; Natera-Kindelán C; Sorlí L; Borrell N; Giner-Oncina L; Amador-Prous C; Shaw E; Jover-Saenz A; Molina J; Martínez-Alvarez RM; Dueñas CJ; Calvo-Montes J; Silva JT; Cárdenes MA; Lecuona M; Pomar V; Valiente de Santis L; Yagüe-Guirao G; Lobo-Acosta MA; Merino-Bohórquez V; Pascual A; Rodríguez-Baño J;
    JAMA Netw Open; 2022 Jan; 5(1):e2137277. PubMed ID: 35024838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Randomized comparative study for the assessment of a new therapeutic schedule of fosfomycin trometamol in postmenopausal women with uncomplicated lower urinary tract infection].
    Palou J; Angulo JC; Ramón de Fata F; García-Tello A; González-Enguita C; Boada A; Sanz M;
    Actas Urol Esp; 2013 Mar; 37(3):147-55. PubMed ID: 22995326
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Fosfomycin trometamol: multiple-dose regimen for the treatment of lower urinary tract infections].
    Sádaba-Díaz de Rada B; Azanza-Perea JR; García-Quetglas E; Honorato-Pérez J
    Enferm Infecc Microbiol Clin; 2006 Nov; 24(9):546-50. PubMed ID: 17125672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral treatment options for patients with urinary tract infections caused by extended spectrum βeta-lactamase (ESBL) producing Enterobacteriaceae.
    Raja NS
    J Infect Public Health; 2019; 12(6):843-846. PubMed ID: 31176606
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Appraisal of Fosfomycin in the Era of Antimicrobial Resistance.
    Sastry S; Clarke LG; Alrowais H; Querry AM; Shutt KA; Doi Y
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7355-61. PubMed ID: 26369978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.